We provide you with 20 years of free, institutional-grade data for ESPR stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ESPR. Explore the full financial landscape of ESPR stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$240,363
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Koenig Sheldon L. | Sale | -53,588 | $3.15 | $169,070 | 2026-06-18 |
| Halladay Benjamin | Sale | -10,773 | $3.15 | $33,989 | 2026-06-18 |
| Looker Benjamin | Sale | -11,824 | $3.15 | $37,305 | 2026-06-18 |
| Shepard Jay | Grant, award...etc | 79,873 | 2026-06-01 | ||
| Hoffman Robert E. | Grant, award...etc | 79,873 | 2026-06-01 | ||
| Fischer Seth H. Z. | Grant, award...etc | 79,873 | 2026-06-01 | ||
| CARROLL J MARTIN | Grant, award...etc | 79,873 | 2026-06-01 | ||
| THOMPSON JOHN CRAIG | Grant, award...etc | 79,873 | 2026-06-01 | ||
| Koenig Sheldon L. | Sale | -25,578 | $2.72 | $69,547 | 2026-03-18 |
| Halladay Benjamin | Sale | -6,424 | $2.71 | $17,377 | 2026-03-18 |
| Looker Benjamin | Sale | -5,708 | $2.7 | $15,429 | 2026-03-18 |
| Looker Benjamin | Grant, award...etc | 300,840 | 2026-03-16 | ||
| Koenig Sheldon L. | Grant, award...etc | 723,760 | 2026-03-16 | ||
| Halladay Benjamin | Grant, award...etc | 247,430 | 2026-03-16 | ||
| Looker Benjamin | Sale | -1,689 | $2.88 | $4,868 | 2026-01-21 |
| Halladay Benjamin | Sale | -7,337 | $3.67 | $26,905 | 2025-12-18 |
| Looker Benjamin | Sale | -6,517 | $3.67 | $23,898 | 2025-12-18 |
| Koenig Sheldon L. | Sale | -48,244 | $3.67 | $177,200 | 2025-12-18 |
| Harlow John B. Jr. | Grant, award...etc | 424,536 | 2025-12-08 | ||
| Looker Benjamin | Sale | -1,248 | $2.62 | $3,275 | 2025-10-20 |
| Halladay Benjamin | Sale | -7,046 | $2.81 | $19,785 | 2025-09-18 |
| Looker Benjamin | Grant, award...etc | 100,000 | 2024-03-15 | ||
| Halladay Benjamin | Grant, award...etc | 170,000 | 2024-03-15 | ||
| Koenig Sheldon L. | Grant, award...etc | 454,000 | 2024-03-15 | ||
| Foody Joanne M. | Grant, award...etc | 150,000 | 2024-03-15 | ||
| Warren Eric | Grant, award...etc | 100,000 | 2024-03-15 |
The information provided in this report about ESPR stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Esperion Therapeutics, Inc(NASDAQ:ESPR) 
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic aci...
Website: http://www.esperion.com
Founded: 1998
Full Time Employees: 193
Sector: Healthcare
Industry: Biotechnology